Clinical Research Directory
Browse clinical research sites, groups, and studies.
Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients
Sponsor: Shinshu University
Summary
The aim of this study is to examine the efficacy and adverse events in the following 3 groups in Japanese osteoporosis patients after 2-year-denosumab therapy: SERM and eldecalcitol treatment for 24 months Bisphosphonates and eldecalcitol treatment for 24 months Eldecalcitol treatment for 24 months
Official title: Examination of Efficacy and Safety of SERM or Bisphosphonates After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients
Key Details
Gender
All
Age Range
20 Years - 120 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2018-11-24
Completion Date
2026-11-23
Last Updated
2021-09-21
Healthy Volunteers
No
Conditions
Interventions
SERM "Viviant®Tablet 20mg" and ELD "Edirol®Tablet 0.75ug"
To examine the effects of SERM and ELD in osteoporosis patients
Bisphosphonates and ELD "Edirol®Tablet 0.75ug"
To examine the effects of BP and ELD in osteoporosis patients
ELD "Edirol®Tablet 0.75ug"
To examine the effects of ELD in osteoporosis patients
Locations (1)
Yukio Nakamura
Matsumoto, Nagano, Japan